Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Neurogenetics of motion laboratory, |
RCV000236780 | SCV000245720 | pathogenic | Hereditary spastic paraplegia 7 | criteria provided, single submitter | case-control | ||
Genome Diagnostics Laboratory, |
RCV001847905 | SCV002105878 | likely pathogenic | Hereditary spastic paraplegia | 2019-03-01 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000236780 | SCV002519811 | pathogenic | Hereditary spastic paraplegia 7 | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000236780 | SCV003922887 | pathogenic | Hereditary spastic paraplegia 7 | 2023-03-15 | criteria provided, single submitter | clinical testing | Variant summary: SPG7 c.2249C>T (p.Pro750Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251330 control chromosomes (gnomAD). c.2249C>T has been reported in the literature in compound heterozygous individuals affected with Hereditary Spastic Paraplegia 7 (Klebe_2012), spastic ataxia (Choquet_2015), and ataxia (Coutelier_2017). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
PROSPAX |
RCV000236780 | SCV005044613 | likely pathogenic | Hereditary spastic paraplegia 7 | 2022-01-01 | criteria provided, single submitter | research |